Immunologic tests

Global In-Vitro Diagnostic Reagents (Antibodies, Oligonucleotide, Nucleic Acid Probe) Markets, 2020-2027

Retrieved on: 
Wednesday, April 14, 2021
Immunologic tests, Biochemistry methods, Immunoassay

The study also evaluates industry competitors and analyzes the market at regional level.\nBased on technology, the immunoassay/immunochemistry segment is estimated to dominate the overall IVD reagents market in 2020.

Key Points: 
  • The study also evaluates industry competitors and analyzes the market at regional level.\nBased on technology, the immunoassay/immunochemistry segment is estimated to dominate the overall IVD reagents market in 2020.
  • The large share of this segment is mainly attributed to the increasing use of immunoassays in infectious disease testing, development of novel tests, and rising demand for immunoassay-based tests.
  • However, the oligonucleotides segment is expected to grow at the fastest CAGR during the forecast period.
  • However, the clinical laboratories segment is expected to register the highest growth during the forecast period, due to the rising number of accredited clinical laboratories; growing collaborations, partnerships, and other strategies undertaken by the key players; and outbreak of COVID-19.\n'

Global COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Medical Device Pipeline Market Assessment 2020-2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 9, 2021
Medical devices, Health, Medical specialties, Clinical medicine, Medicine, Immunologic tests, Laboratory techniques, ELISA, Assay, ELISA, Immunology, Palaeoimmunology, Virus quantification

The "COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.
  • "COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • COVID 19 EIA/ELISA are the most widely used assays having high sensitivity and specificity.
  • They are used to detect the recombinant protein and peptide antigens in the samples.

BrainChip Research Enter into a Research Collaboration with Biotome for SARS-CoV-2 Antibody Detection

Retrieved on: 
Tuesday, April 6, 2021
Software, Biotechnology, Nanotechnology, Health, Medical devices, Infectious diseases, Technology, Semiconductor, Immunology, Antibody, Glycoproteins, Branches of biology, Immunologic tests, Health, Biology, Biotome Pty Ltd., BrainChip Holdings Ltd (ASX: BRN)

BrainChip Holdings Ltd (ASX: BRN), a leading provider of ultra-low power high performance artificial intelligence technology, today announced that the Brainchip Research Institute in Perth has entered into a research collaboration with precision immunology company Biotome Pty Ltd. Biotome is developing highly accurate antibody tests for infections.

Key Points: 
  • BrainChip Holdings Ltd (ASX: BRN), a leading provider of ultra-low power high performance artificial intelligence technology, today announced that the Brainchip Research Institute in Perth has entered into a research collaboration with precision immunology company Biotome Pty Ltd. Biotome is developing highly accurate antibody tests for infections.
  • Dr. Samuel Lundin, CEO of Biotome said: We believe the precision of antibody tests for infections can be improved dramatically.
  • Our partnership with Brainchip is an important step for our development of point-of-care tests that are based on patented high-precision immunological markers.
  • If the project is successful we will apply the same principles to other antibody tests in our pipeline.

Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test

Retrieved on: 
Thursday, April 1, 2021
Medical specialties, Branches of biology, Antibodies, Glycoproteins, Medicine, Immunologic tests, Neutralizing antibody, Immunoassay, Immunoglobulin G, Reporter virus particles, COVID-19 testing

SAN DIEGO, April 01, 2021 (GLOBE NEWSWIRE) -- Diazyme Laboratories, Inc. announced March 30th that it has obtained CE-IVD marking for its SARS-CoV-2 neutralizing antibody test.

Key Points: 
  • SAN DIEGO, April 01, 2021 (GLOBE NEWSWIRE) -- Diazyme Laboratories, Inc. announced March 30th that it has obtained CE-IVD marking for its SARS-CoV-2 neutralizing antibody test.
  • The Diazyme test is a high throughput chemiluminescent immunoassay with excellent correlation to a fluorescence based neutralization assay, which has been used to evaluate the adaptive immune response in vaccine studies1.
  • Unlike the widely available total SARS-CoV-2 IgG antibody tests, Diazymes neutralizing antibody test measures the subset of neutralizing antibodies that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein and the human ACE2 cell surface receptor.
  • The Diazyme neutralizing antibody test gives the scientific community and health authorities a valuable tool to evaluate the level of effective antibodies generated after infection or vaccination, and to assess adaptive immunity in studies going forward.

Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu

Retrieved on: 
Thursday, April 1, 2021
Health, Medicine, Clinical medicine, Immunologic tests, Clinical Laboratory Improvement Amendments, Healthcare in the United States, Severe acute respiratory syndrome, COVID-19, Immunoassay, DiaSorin

Product inventory is on-hand and immediately available for shipment to customers across the United States.

Key Points: 
  • Product inventory is on-hand and immediately available for shipment to customers across the United States.
  • The rapid immunoassay test is approved for use in laboratories with a CLIA waiver license, produces results in 15 minutes and requires no instrumentation.
  • The test simultaneously differentiates SARS-CoV-2 antigens and influenza Type A and Type B infections from a single swab.
  • Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease.

Meridian Bioscience Announces FDA Submission for New Curian® Campy Assay

Retrieved on: 
Thursday, April 1, 2021
Chemistry, Physical sciences, Natural sciences, Laboratory techniques, Meridian Bioscience, Immunologic tests, Epsilonproteobacteria, Assay, Lateral flow test, Campylobacter

CINCINNATI, April 01, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Companys new Curian Campy assay.

Key Points: 
  • CINCINNATI, April 01, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Companys new Curian Campy assay.
  • This assay is one of many assays in the pipeline that expands the Curian menu, continuing Meridians leadership in the gastrointestinal disease and lateral flow testing market.
  • Curian Campy, for use with the Curian Analyzer, is a rapid, qualitative fluorescent immunoassay for the detection of Campylobacter spp.
  • Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.

Abbott's BinaxNOW™ Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counter, Non-Prescription, Multi-Test Use

Retrieved on: 
Thursday, April 1, 2021
Medicine, Immunologic tests, Clinical medicine, Health sciences, COVID-19, Occupational safety and health, Public health, Zoonoses, Emergency Use Authorization, Immunoassay, COVID-19 testing, Rapid antigen test

The BinaxNOW Self Test is the same technology as the existing BinaxNOW test that has been available since August 2020 but is indicated by the FDA for serial asymptomatic testing, meaning that people should test themselves frequently.

Key Points: 
  • The BinaxNOW Self Test is the same technology as the existing BinaxNOW test that has been available since August 2020 but is indicated by the FDA for serial asymptomatic testing, meaning that people should test themselves frequently.
  • The BinaxNOW COVID-19 Ag Card Self Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2.
  • BinaxNOW COVID-19 Ag Card Self Test is only for use under the Food and Drug Administration's Emergency Use Authorization.
  • The BinaxNOW COVID-19 Ag Card 2 Home Test is to be performed only with the supervision of a telehealth proctor.

Immunoassay Market to Reach $43.51 Billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis and Forecasts by Meticulous Research®

Retrieved on: 
Tuesday, March 30, 2021
Immunologic tests, Biochemistry methods, Chemistry, Physical sciences, Natural sciences, Immunoassay, ELISA, Assay, Siemens Healthineers, Enzyme immunoassay, DiaSorin

Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.

Key Points: 
  • Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.
  • Through all these advances, the usage of immunoassay is further expected to expand, supporting market growth in upcoming years.
  • On the basis of product and solution, the immunoassay kits and reagents segment accounted for the largest share of the overall immunoassays market.
  • For instance, in February 2021, Siemens Healthineers AG (Germany) received the CE mark approval for its SARS-CoV-2 Antigen Assay (CoV2Ag).

Immunoassay Market to Reach $43.51 Billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis and Forecasts by Meticulous Research®

Retrieved on: 
Tuesday, March 30, 2021
Immunologic tests, Biochemistry methods, Chemistry, Physical sciences, Natural sciences, Immunoassay, ELISA, Assay, Siemens Healthineers, Enzyme immunoassay, DiaSorin

Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.

Key Points: 
  • Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.
  • Through all these advances, the usage of immunoassay is further expected to expand, supporting market growth in upcoming years.
  • On the basis of product and solution, the immunoassay kits and reagents segment accounted for the largest share of the overall immunoassays market.
  • For instance, in February 2021, Siemens Healthineers AG (Germany) received the CE mark approval for its SARS-CoV-2 Antigen Assay (CoV2Ag).

DeepVerge PLC: Microtox® BT Evaluation of SARS-CoV-2 from breath test with Clinical Samples

Retrieved on: 
Wednesday, March 17, 2021
Breath tests, Respiration, Immunologic tests, Medical tests

The breath samples detected binding on the nano-optofluidic chip with a secondary antibody to the Spike Protein which was initially selected for the isolated spike protein work.

Key Points: 
  • The breath samples detected binding on the nano-optofluidic chip with a secondary antibody to the Spike Protein which was initially selected for the isolated spike protein work.
  • Further data is required to confirm the same high sensitivity and specificity is achieved on breath test clinical trials which are underway.
  • Gerard Brandon CEO of DeepVerge plc commented:
    "DeepVerge scientists have transformed its AI based water contamination detection system, developed over five years for e.coli, into the breath condensate MicrotoxBT unit.
  • "The requirement for the UK Target Product Profile ("TPP") Rapid Breath Test requires 150 confirmed positive samples and 250 confirmed negative samples.